'Interpark Bio Convergence' Established... Promoting New Drug Development Business

Appointment of Hong Junho as CEO and Head of Planning and Coordination Office, Recruitment of Internal Medicine Specialist Lee Sangyun as Research Director
Collaboration Plan from Early Drug Development to Clinical Research with Research Team Led by Cho Byungchul, Head of Yonsei Cancer Hospital Lung Cancer Center

[Asia Economy Reporter Kim Cheol-hyun] Interpark announced on the 3rd that it has spun off its affiliated research institute, the Bio Convergence Research Institute, to establish a separate corporation called 'Interpark Bio Convergence.'

Interpark plans to pursue a business of researching and developing new drugs through the newly established company Interpark Bio Convergence using a 'convergence method.' Unlike the existing new drug development centered on proprietary technology and research, this approach actively selects new drugs needed by the market by reflecting trend analysis and the actual needs of medical sites, then gathers and integrates optimized technologies and personnel to operate on a project basis. In addition, the 'organoid (similar organ)' technology, which the existing Bio Convergence Research Institute has been conducting, will be utilized as one pillar of new drug research and development.

To this end, Hong Jun-ho, head of planning and coordination at the research institute who has led new businesses within the Interpark group, was appointed CEO of Interpark Bio Convergence, and Lee Sang-yoon, an internal medicine specialist who served as Medical Director for Pfizer Korea and Japan, was recruited as the head of the research institute. Furthermore, they plan to closely collaborate with the research team led by Cho Byung-chul, head of the Lung Cancer Center at Yonsei Cancer Hospital, who plays a leading role in multinational clinical research, from early-stage new drug development to clinical trials.

They also plan to expand the talent pool to enhance the efficiency of the convergence development method by forming a part-time research staff or advisory group consisting of top experts in various fields related to new drug development active in major domestic general hospitals as well as in the United States, Europe, and Japan. Based on market analysis results such as the US FDA new drug approval trends related to new drug development, Interpark Bio Convergence plans to initially focus on developing anticancer drugs and later expand the development scope to various fields.

Hong Jun-ho, CEO of Interpark Bio Convergence, said, "We will focus on creating a research environment where various open innovations are actively carried out and, at the same time, a selection and concentration strategy can be boldly executed," adding, "We will do our best to become a bio company competitive in the global market."

This content was produced with the assistance of AI translation services.